Compare Organon & Co. Common Stock (OGN) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Health Care Select Sector SPDR Fund — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Health Care Select Sector SPDR Fund trades at $176.53 (market cap $43.92B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 12.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| OGN | XLV | |
|---|---|---|
Market Cap | $3.61B | $43.92B |
Volume | 1,808,049 | 11,816,834 |
Sector | Health | — |
52-Week High | $13.81 | $175.68 |
52-Week Low | $5.70 | $142.33 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
XLV trades at $169.66, down 1.35% today, while maintaining a bullish technical outlook with strong moving average signals. The healthcare ETF's low 0.08% expense ratio and diversified exposure to 61 S&P 500 healthcare stocks provide cost-effective sector access. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and political volatility.
Outlook remains positive given healthcare's defensive positioning amid economic uncertainty, though overbought RSI levels suggest near-term consolidation. Key risks include sector-specific regulatory pressures and election-related policy uncertainty that could impact healthcare stocks through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
